AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...

AstraZeneca's hopes for baxdrostat are high, as in early 2023 it acquired the drug by purchasing its developer -- biotech ...

AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s cancer drugs despite a potential patent infringement risk. Monday, AZ said ...

Virginia will be home to a workforce training center preparing thousands of people each year for a career in the pharmaceutical industry.

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

AstraZeneca, Eli Lilly and Merck committed $120 million to develop an advanced pharmaceutical manufacturing training center in Central Virginia.

Global pharmaceutical manufacturer and biotech company AstraZeneca plans to construct a multibillion dollar manufacturing center focused on chronic diseases in Virginia within the next five years, it ...

President Trump hailed his deal with pharma companies on GLP-1 drug pricing. The question is how big of a difference the deal ...